Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CALCA | P06881 | 1/20 | 0.45 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129643 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2SRCLMNACALCANAPEPLD | |
| SCHEMBL30795947 | 0.97 | SRC (0.49) | SRCLMNANAPEPLDPIK3CATP53 | |
| SCHEMBL2134192 | 0.97 | SRC (0.49) | SRCLMNANAPEPLDPIK3CATP53 | |
| SCHEMBL2129359 | 0.88 | SRC (0.49) | SMN1; SMN2SRCLMNANAPEPLDPIK3CA | |
| SCHEMBL2133149 | 0.88 | SRC (0.49) | SRCNAPEPLDPIK3CAPIK3CBPIK3CD | |
| SCHEMBL2132270 | 0.87 | SRC (0.48) | SRCLMNATP53ALDH1A1HPGD | |
| SCHEMBL2128348 | 0.87 | KCNQ3 (0.48) | SMN1; SMN2SRCLMNANAPEPLDPIK3CA | |
| SCHEMBL30795803 | 0.86 | SRC (0.47) | SRCLMNANAPEPLDPIK3CAPIK3CB | |
| SCHEMBL2129743 | 0.86 | SRC (0.47) | SRCLMNANAPEPLDPIK3CAPIK3CB | |
| SCHEMBL2128983 | 0.85 | SRC (0.47) | SRCLMNANAPEPLDPIK3CATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |